{"result": "(\"entity\"<|>ZUGASTI A.<|>PERSON<|>Zugasti A. is an author who contributed to research on hepatopathy associated with parenteral nutrition and lipid emulsions.)\n##\n(\"entity\"<|>PETRINA E.<|>PERSON<|>Petrina E. is a co-author of a study on hepatopathy related to parenteral nutrition and lipid emulsions.)\n##\n(\"entity\"<|>ELIZONDO J.<|>PERSON<|>Elizondo J. is a researcher involved in the study of hepatopathy associated with parenteral nutrition and lipid emulsions.)\n##\n(\"entity\"<|>VANEK VW<|>PERSON<|>Vanek VW is an author of a position paper discussing the clinical role of alternative intravenous fat emulsions.)\n##\n(\"entity\"<|>SEIDNER DL<|>PERSON<|>Seidner DL is a co-author of clinical guidelines regarding nutrition support for patients with hyperglycemia.)\n##\n(\"entity\"<|>ALLEN P.<|>PERSON<|>Allen P. is a contributor to the A.S.P.E.N. position paper on intravenous fat emulsions.)\n##\n(\"entity\"<|>DRUML W.<|>PERSON<|>Druml W. is a researcher who studied fat elimination in chronic hepatic failure.)\n##\n(\"entity\"<|>FISCHER M.<|>PERSON<|>Fischer M. is a co-author of research on fat elimination in chronic hepatic failure.)\n##\n(\"entity\"<|>PIDLICH J.<|>PERSON<|>Pidlich J. is a researcher involved in the study of fat elimination in chronic hepatic failure.)\n##\n(\"entity\"<|>LENZ K.<|>PERSON<|>Lenz K. is a co-author of research on fat elimination in chronic hepatic failure.)\n##\n(\"entity\"<|>BECVAROVA I.<|>PERSON<|>Becvarova I. is a researcher who studied peroxidative protection of parenteral admixtures.)\n##\n(\"entity\"<|>SAKER KE.<|>PERSON<|>Saker KE is a co-author of research on peroxidative protection in parenteral nutrition.)\n##\n(\"entity\"<|>SWECKER WS JR.<|>PERSON<|>Swecker WS Jr. is a researcher involved in the study of peroxidative protection in parenteral nutrition.)\n##\n(\"entity\"<|>TROY GC.<|>PERSON<|>Troy GC is a co-author of research on peroxidative protection in parenteral nutrition.)\n##\n(\"entity\"<|>MEIJER VE.<|>PERSON<|>Meijer VE is a researcher who studied parenteral fish oil monotherapy for liver disease.)\n##\n(\"entity\"<|>GURA KM.<|>PERSON<|>Gura KM is a co-author of research on parenteral fish oil monotherapy.)\n##\n(\"entity\"<|>MEISEL JA.<|>PERSON<|>Meisel JA is a researcher involved in the study of parenteral fish oil monotherapy.)\n##\n(\"entity\"<|>LE HD.<|>PERSON<|>Le HD is a co-author of research on parenteral fish oil monotherapy.)\n##\n(\"entity\"<|>PUDER M.<|>PERSON<|>Puder M. is a researcher who studied parenteral fish oil monotherapy for liver disease.)\n##\n(\"entity\"<|>WANTEN GJ.<|>PERSON<|>Wanten GJ is a researcher who studied immune modulation by parenteral lipid emulsions.)\n##\n(\"entity\"<|>CALDER PC.<|>PERSON<|>Calder PC is a co-author of research on immune modulation by parenteral lipid emulsions.)\n##\n(\"entity\"<|>KRAFT MD.<|>PERSON<|>Kraft MD is a researcher who reviewed phosphorus and calcium in nutrition support.)\n##\n(\"entity\"<|>MARTINEZ MJ.<|>PERSON<|>Martinez MJ is a researcher who studied hypophosphatemia in postoperative patients on total parenteral nutrition.)\n##\n(\"entity\"<|>MATRINEZ MA.<|>PERSON<|>Matrinez MA is a co-author of research on hypophosphatemia in postoperative patients.)\n##\n(\"entity\"<|>MONTERO M.<|>PERSON<|>Montero M. is a researcher involved in the study of hypophosphatemia in postoperative patients.)\n##\n(\"entity\"<|>CAMPELO E.<|>PERSON<|>Campelo E. is a co-author of research on hypophosphatemia in postoperative patients.)\n##\n(\"entity\"<|>CASTRO I.<|>PERSON<|>Castro I. is a researcher involved in the study of hypophosphatemia in postoperative patients.)\n##\n(\"entity\"<|>INARAJA MT.<|>PERSON<|>Inaraja MT is a co-author of research on hypophosphatemia in postoperative patients.)\n##\n(\"entity\"<|>FERNÁNDEZ LÓPEZ MT.<|>PERSON<|>Fernández López MT is a researcher who studied refeeding syndrome.)\n##\n(\"entity\"<|>LÓPEZ OTERO MJ.<|>PERSON<|>López Otero MJ is a co-author of research on refeeding syndrome.)\n##\n(\"entity\"<|>ÁLVAREZ VÁZQUEZ P.<|>PERSON<|>Álvarez Vázquez P. is a researcher involved in the study of refeeding syndrome.)\n##\n(\"entity\"<|>ARIAS DELGADO J.<|>PERSON<|>Arias Delgado J. is a co-author of research on refeeding syndrome.)\n##\n(\"entity\"<|>OLVEIRA G.<|>PERSON<|>Olveira G. is a researcher who studied hyperglycemia in hospitalized patients on total parenteral nutrition.)\n##\n(\"entity\"<|>TAPIA MJ.<|>PERSON<|>Tapia MJ is a co-author of research on hyperglycemia in hospitalized patients.)\n##\n(\"entity\"<|>OCÓN J.<|>PERSON<|>Ocón J. is a researcher involved in the study of hyperglycemia in hospitalized patients.)\n##\n(\"entity\"<|>PASQUEL FJ.<|>PERSON<|>Pasquel FJ is a researcher who studied hyperglycemia during total parenteral nutrition.)\n##\n(\"entity\"<|>SPIEGELMAN R.<|>PERSON<|>Spiegelman R. is a co-author of research on hyperglycemia during total parenteral nutrition.)\n##\n(\"entity\"<|>MCCAULEY M.<|>PERSON<|>McCauley M. is a researcher involved in the study of hyperglycemia during total parenteral nutrition.)\n##\n(\"entity\"<|>LIN LY.<|>PERSON<|>Lin LY is a researcher who studied hyperglycemia correlating with outcomes in patients receiving total parenteral nutrition.)\n##\n(\"entity\"<|>LIN HC.<|>PERSON<|>Lin HC is a co-author of research on hyperglycemia in patients receiving total parenteral nutrition.)\n##\n(\"entity\"<|>LEE PC.<|>PERSON<|>Lee PC is a researcher involved in the study of hyperglycemia in patients receiving total parenteral nutrition.)\n##\n(\"entity\"<|>MA WY.<|>PERSON<|>Ma WY is a co-author of research on hyperglycemia in patients receiving total parenteral nutrition.)\n##\n(\"entity\"<|>LIN HD.<|>PERSON<|>Lin HD is a researcher who studied hyperglycemia in patients receiving total parenteral nutrition.)\n##\n(\"relationship\"<|>ZUGASTI A.<|>PETRINA E.<|>Zugasti A. and Petrina E. co-authored research on hepatopathy associated with parenteral nutrition<|>6)\n##\n(\"relationship\"<|>ZUGASTI A.<|>ELIZONDO J.<|>Zugasti A. and Elizondo J. co-authored research on hepatopathy associated with parenteral nutrition<|>6)\n##\n(\"relationship\"<|>VANEK VW<|>SEIDNER DL<|>Vanek VW and Seidner DL co-authored a position paper on intravenous fat emulsions<|>6)\n##\n(\"relationship\"<|>DRUML W.<|>FISCHER M.<|>Druml W. and Fischer M. co-authored research on fat elimination in chronic hepatic failure<|>6)\n##\n(\"relationship\"<|>BECVAROVA I.<|>SAKER KE.<|>Becvarova I. and Saker KE co-authored research on peroxidative protection in parenteral nutrition<|>6)\n##\n(\"relationship\"<|>MEIJER VE.<|>GURA KM.<|>Meijer VE and Gura KM co-authored research on parenteral fish oil monotherapy<|>6)\n##\n(\"relationship\"<|>WANTEN GJ.<|>CALDER PC.<|>Wanten GJ and Calder PC co-authored research on immune modulation by parenteral lipid emulsions<|>6)\n##\n(\"relationship\"<|>MARTINEZ MJ.<|>MATRINEZ MA.<|>Martinez MJ and Matrinez MA co-authored research on hypophosphatemia in postoperative patients<|>6)\n##\n(\"relationship\"<|>OLVEIRA G.<|>TAPIA MJ.<|>Olveira G. and Tapia MJ co-authored research on hyperglycemia in hospitalized patients<|>6)\n##\n(\"relationship\"<|>PASQUEL FJ.<|>SPIEGELMAN R.<|>Pasquel FJ and Spiegelman R. co-authored research on hyperglycemia during total parenteral nutrition<|>6)\n##\n(\"relationship\"<|>LIN LY.<|>LIN HC.<|>Lin LY and Lin HC co-authored research on hyperglycemia correlating with outcomes in patients receiving total parenteral nutrition<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ol- and phospholipid-rich particles of commercial parentral fat emulsions.Nutrition.1999 Jan; 15(1): 44-50.\n\n39. Zugasti A., Petrina E., Elizondo J. Hepatopatía asociada a nutrición parenteral y emulsiones lipídicas Endocrinologia y Nutricion, 2015 (62): 285-289.\n\n40. Vanek VW, Seidner DL, Allen P, et al. A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions. Nutr Clin Pract.2012; 27(2): 150-192.\n\n41. Druml W, Fischer M, Pidlich J, Lenz K. Fat elimination in chronic hepatic failure: long-chain vs medium-chain triglycerides. Am J Clin Nutr.1995; 61(4): 812-817.\n\n42. Becvarova I, Saker KE, Swecker WS Jr, Troy GC. Peroxidative protection of parenteral admixture by D-alpha-tocopherol. Vet Therapeut. 2005; 6(4): 280-290.\n\n43. Meijer VE, Gura KM, Meisel JA, Le HD, Puder M. Parenteral fish oil monotherapy in the management of patients with parenteral nutrition– associated liver disease. Arch Surg. 2010; 145(6): 547-551.\n\n44. Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 2007; 85: 1171-1184.\n\n45. Seidner DL. Parenteral nutrition-associated metabolic bone disease. JPEN J Parenter Enteral Nutr. 2002; 26: S37-S42.\n\n46. Kraft MD. Phosphorus and Calcium: A Review for the Adult Nutrition Support Clinician Nutrition in Clinical Practice Volume 30 Number 1 February 2015 21–33.\n\n47. Multivitamin preparations for parenteral use. A statement by the Nutrition Advisory Group. American Medical Association Department of Foods and Nutrition, 1975. JPEN J Parenter Enteral Nutr 1979; 3: 258-262.\n\n48. Vanek VW, Borum P, Buchman A, et al. ASPEN position paper recommendations for changes in commercially available parenteralmultivitamin and multi-trace element products. Nutr Clin Pract. 2012; 27(4): 440-491.\n\n49. Walmsley RS Refeeding syndrome: Screening, incidence, and treatment during parenteral nutrition Journal of Gastroenterology and Hepatology 2013; 28 (4): 113–117.\n---\nTema 48. Nutrición parenteral 777\n\n50. Shenkin A. Selenium in intravenous nutrition. Gastroenterology. 2009; 137(5): S61-S69.\n51. Forbes A. Iron and parenteral nutrition. Gastroenterology.2009; 137(5): S47-S54.\n52. NICE guidelines 2006. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition.\n53. Martinez MJ, Matrinez MA, Montero M, Campelo E, Castro I, Inaraja MT. Hypophosphatemia in postoperative patients on total parenteral nutrition: influence of nutritional support teams. Nutr Hosp 2006; 21: 657-60).\n54. Fernández Lópeza MT, López Oterob MJ, Álvarez Vázqueza P, Arias Delgado J. arela Correa JJ Síndrome de realimentación Farm Hosp. 2009; 33(4): 183-193.\n55. McMahon MM, Nystrom E, Braunschweig C, Miles J, Compher C, A.S.P.E.N. Board of Directors. A.S.P.E.N. Clinical Guidelines: Nutrition Support of Adult Patients With Hyperglycemia. JPEN J Parenter Enteral Nutr 2013; 37: 23-36.\n56. Endocr Pract. 2015 Jan; 21(1): 59-67. doi: 10.4158/EP13441.OR. Prevalence of diabetes, prediabetes, and stress hyperglycemia: insulin therapy and metabolic control in patients on total parenteral nutrition (prospective multicenter study).\n57. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 16-38.\n58. Olveira G, Tapia MJ, Ocón J, et al. Parenteral nutrition-associated hyperglycemia in non-critically ill inpatients increases the risk of in-hospital mortality (multicenter study) Diabetes Care 2013; 36: 1061-6.\n59. Pasquel FJ, Spiegelman R, McCauley M, et al. Hyperglycemia during total parenteral nutrition: an important marker of poor outcome and mortality in hospitalized patients. Diabetes Care. 2010; 33(4): 739-741.\n60. Lin LY, Lin HC, Lee PC, Ma WY, Lin HD. Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition. Am J MedSci. 2007; 333(5): 261-265.\n61. Olveira G, Garcia-L\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>A.S.P.E.N.<|>ORGANIZATION<|>A.S.P.E.N. (American Society for Parenteral and Enteral Nutrition) is an organization that provides guidelines and position papers on nutrition support, particularly in parenteral nutrition.)\n##\n(\"entity\"<|>NUTRITION ADVISORY GROUP<|>ORGANIZATION<|>The Nutrition Advisory Group is a committee within the American Medical Association that focuses on nutrition-related guidelines and recommendations.)\n##\n(\"entity\"<|>AMERICAN MEDICAL ASSOCIATION<|>ORGANIZATION<|>The American Medical Association is a professional association that publishes guidelines and statements regarding medical practices, including nutrition.)\n##\n(\"entity\"<|>GASTROENTEROLOGY<|>EVENT<|>Gastroenterology is a medical field that deals with the digestive system and its disorders, often discussed in the context of nutrition and parenteral nutrition.)\n##\n(\"entity\"<|>NUTRITION SUPPORT TEAMS<|>ORGANIZATION<|>Nutrition Support Teams are specialized groups that provide nutritional care and support to patients, particularly those on parenteral nutrition.)\n##\n(\"entity\"<|>HYPERGLYCEMIA<|>EVENT<|>Hyperglycemia is a condition characterized by high blood sugar levels, often discussed in relation to patients receiving parenteral nutrition.)\n##\n(\"entity\"<|>POSTOPERATIVE PATIENTS<|>PERSON<|>Postoperative patients are individuals who have undergone surgery and may require specialized nutritional support, including parenteral nutrition.)\n##\n(\"entity\"<|>TOTAL PARENTERAL NUTRITION<|>EVENT<|>Total parenteral nutrition is a method of feeding that bypasses the gastrointestinal tract, providing nutrients directly into the bloodstream.)\n##\n(\"entity\"<|>NICE GUIDELINES<|>ORGANIZATION<|>NICE (National Institute for Health and Care Excellence) provides guidelines for nutrition support in adults, including oral and parenteral nutrition.)\n##\n(\"entity\"<|>DIABETES CARE<|>EVENT<|>Diabetes Care is a field of medicine that focuses on the management and treatment of diabetes, often relevant in discussions of parenteral nutrition.)\n##\n(\"relationship\"<|>A.S.P.E.N.<|>NUTRITION ADVISORY GROUP<|>A.S.P.E.N. collaborates with the Nutrition Advisory Group to develop guidelines for parenteral nutrition<|>7)\n##\n(\"relationship\"<|>A.S.P.E.N.<|>AMERICAN MEDICAL ASSOCIATION<|>A.S.P.E.N. is associated with the American Medical Association in providing nutrition guidelines<|>7)\n##\n(\"relationship\"<|>NUTRITION SUPPORT TEAMS<|>POSTOPERATIVE PATIENTS<|>Nutrition Support Teams provide care for postoperative patients requiring parenteral nutrition<|>8)\n##\n(\"relationship\"<|>HYPERGLYCEMIA<|>TOTAL PARENTERAL NUTRITION<|>Hyperglycemia is a common complication in patients receiving total parenteral nutrition<|>9)\n##\n(\"relationship\"<|>NICE GUIDELINES<|>A.S.P.E.N.<|>NICE guidelines are often referenced by A.S.P.E.N. for best practices in nutrition support<|>6)\n##\n(\"relationship\"<|>DIABETES CARE<|>HYPERGLYCEMIA<|>Diabetes Care addresses the management of hyperglycemia, particularly in patients on parenteral nutrition<|>8)\n<|COMPLETE|>"}]}